Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00002052
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service

Brief Summary:
To compare the effectiveness of standard treatment with parenteral ampicillin and oral amoxicillin compared to initial daily therapy with ceftriaxone followed by 3 times weekly suppressive treatment for salmonella infections in AIDS patients.

Condition or disease Intervention/treatment Phase
HIV Infections Salmonella Infections Drug: Ceftriaxone sodium Drug: Ampicillin sodium Drug: Amoxicillin trihydrate Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Type I hypersensitivity to beta-lactam antibiotics.
  • Not expected to survive 12 weeks.
  • In a coma or with other central nervous system (CNS) impairment.

Patients with the following are excluded:

  • Type I hypersensitivity to beta-lactam antibiotics.
  • Not expected to survive 12 weeks.
  • In a coma or with other central nervous system (CNS) impairment.

Prior Medication:

Excluded within 48 hours of study entry:

  • Treatment with an antibiotic active in vitro against Salmonella.

HIV infection, AIDS, or AIDS related complex (ARC).

  • Salmonella bacteremia or positive stool culture in patient with 3 or more stools per day.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002052


Locations
Layout table for location information
United States, California
Los Angeles County - USC Med Ctr
Los Angeles, California, United States, 90033
Sponsors and Collaborators
University of Southern California
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00002052    
Other Study ID Numbers: 019A
First Posted: August 31, 2001    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: August 1989
Keywords provided by NIH AIDS Clinical Trials Information Service:
Salmonella Infections
AIDS-Related Opportunistic Infections
Acquired Immunodeficiency Syndrome
Amoxicillin
Ceftriaxone
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Salmonella Infections
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Amoxicillin
Ceftriaxone
Ampicillin
Anti-Bacterial Agents
Anti-Infective Agents